ITGAM and melanoma: Interestingly, while PMN-MDSC (CD11b+Ly6g+) frequencies were not altered between the treatment cohorts, PD-L1 expression on PMN-MDSCs was reduced in B16 melanomas treated with ADU-S100 + anti-PD-L1 vs. ADU-S100 alone (Supplementary Figure 4B).